In this exclusive interview
conducted ahead of this year’s Cell and Gene Therapy Manufacturing conference,
Simon Briggs, Product Steward Cell and Gene Therapy Unit –
Kymriah, C&G Technical Operations, Novartis shares his views on how to successfully achieve commercialisation.
With
increased pressures on process scalability and regulatory compliance, Simon
Briggs highlights some of the challenges and solutions Novartis have faced when transitioning from clinical to
commercialisation.
Download our latest interview to get the answers to the following questions:
Please note: That all fields marked with an asterisk (*) are required.